LDN-212854 is a potent and selective small molecule inhibitor of the bone morphogenetic protein (BMP) type I receptor ALK2 (also known as ACVR1). It is primarily utilized in research settings to study BMP signaling pathways, which are critical for bone development, tissue differentiation, and homeostasis. This compound has demonstrated efficacy in preclinical models for inhibiting aberrant ALK2 activity, making it a valuable tool for investigating genetic disorders such as fibrodysplasia ossificans progressiva (FOP), a rare condition leading to progressive heterotopic ossification of soft tissues. Researchers also explore its potential in cancer biology, where dysregulated BMP signaling contributes to tumor progression, and in other developmental and inflammatory diseases. Further studies are ongoing to elucidate its therapeutic applications and pharmacological properties.